Literature DB >> 18030652

Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.

B Gallhofer1, P Jaanson, A Mittoux, P Tanghøj, S Lis, S Krieger.   

Abstract

OBJECTIVE: To compare the impact of sertindole and haloperidol on cognitive function in patients suffering from schizophrenia.
METHODS: In a 12 week trial, of the 40 patients randomised to treatment, 34 (17 sertindole and 17 haloperidol) were included in the analysis set. Cognitive sub-processes were investigated with the Reaction Time Decomposition (RTD) method and the Wisconsin Card Sorting Test (WCST), at baseline, Week 4 and Week 12.
RESULTS: In executive function, i.e. set shifting tasks, sertindole reversed cognitive deficits significantly more than haloperidol. It was demonstrated that this atypical drug improved cognitive processing independently of motor function. Patients receiving sertindole markedly improved on the RTD task at Week 4 and continued to improve (although at a slower rate) at Week 12, those patients receiving haloperidol showed marked impairment at Week 4 with partial recovery by Week 12.
CONCLUSION: The study demonstrated two distinct processes of action on cognition between sertindole and haloperidol and the marked beneficial effects of sertindole, particularly in parameters that are regarded as schizophrenia-related cognitive disturbances.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030652     DOI: 10.1055/s-2007-990291

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  14 in total

1.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 2.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

3.  Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole.

Authors:  Felice Iasevoli; Carmine Tomasetti; Federica Marmo; Daniele Bravi; Jørn Arnt; Andrea de Bartolomeis
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

Review 4.  Emerging treatments in the management of schizophrenia - focus on sertindole.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Salvatore Settineri; Rocco Zoccali
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

5.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

6.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Authors:  Brian Villumsen Broberg; Birte Yding Glenthøj; Rebecca Dias; Dorrit Bjerg Larsen; Christina Kurre Olsen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

7.  Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.

Authors:  Nagi Idris; Jo Neill; Ben Grayson; Benny Bang-Andersen; Louise M Witten; Lise Tøttrup Brennum; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2009-10-23       Impact factor: 4.530

8.  Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia.

Authors:  René Ernst Nielsen; Florence Odur; Torben Ostergaard; Povl Munk-Jørgensen; Jimmi Nielsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

9.  Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.

Authors:  Pascal Goetghebeur; Rebecca Dias
Journal:  Psychopharmacology (Berl)       Date:  2008-04-08       Impact factor: 4.530

10.  The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice.

Authors:  Tomasz Kos; Agnieszka Nikiforuk; Dominik Rafa; Piotr Popik
Journal:  Psychopharmacology (Berl)       Date:  2010-12-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.